Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa study of SKLB1028 capsules in FLT3-mutated relapsed/refractory AML
CTR20190952Phase 2Completed
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruserontinib in acute myeloid leukemia (AML), sponsored by CSPC ZhongQi Pharmaceutical Technology. Started May 2019; status: completed.
02
Drugs
ruserontinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on CTR20190952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190952.